Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | XBP1 | P17861 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.42 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.41 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.41 |
| ▸ | PLK1 | P53350 | 1/20 | 0.39 |
| ▸ | TARBP2 | Q15633 | 2/20 | 0.38 |
| ▸ | GLP1R | P43220 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29620502 | 1.00 | NPC1 (0.42) | NPC1ALDH1A1TP53MAPTXBP1 | |
| SCHEMBL10177625 | 0.88 | ALDH1A1 (0.43) | NPC1ALDH1A1TP53MAPTXBP1 | |
| SCHEMBL10177635 | 0.81 | MAPT (0.43) | NPC1ALDH1A1TP53MAPTXBP1 | |
| SCHEMBL2743308 | 0.81 | NPC1 (0.46) | NPC1ALDH1A1TP53MAPTXBP1 | |
| SCHEMBL13472307 | 0.81 | KDM5B (0.48) | NPC1ALDH1A1TP53MAPTXBP1 | |
| SCHEMBL22118282 | 0.78 | NPC1 (0.43) | NPC1ALDH1A1TP53MAPTXBP1 | |
| SCHEMBL18703764 | 0.78 | NPC1 (0.47) | NPC1ALDH1A1TP53MAPTXBP1 | |
| SCHEMBL28855951 | 0.78 | ALDH1A1 (0.43) | NPC1ALDH1A1TP53MAPTXBP1 | |
| SCHEMBL16274616 | 0.75 | CA12 (0.48) | NPC1ALDH1A1TP53MAPTXBP1 | |
| SCHEMBL15350459 | 0.75 | CYP4F2 (0.50) | ALDH1A1MAPTHTTHSD17B10CYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4041732-B1 | ISO-CITRATE DEHYDROGENASE (IDH) INHIBITOR | ZHEJIANG METON PHARMACEUTICAL CO LTD (CN) | 2026-03-18 | — | — | EP | disclosed |
| US-12528802-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-01-20 | — | — | US | disclosed |
| US-12441725-B2 | ISO-citrate dehydrogenase (IDH) inhibitor | ZHEJIANG METON PHARMACEUTICAL CO., LTD (CN) | 2025-10-14 | — | — | US | disclosed |
| CN-114555597-B | Isocitrate Dehydrogenase (IDH) inhibitors | 浙江迈同生物医药有限公司 | 2024-06-04 | — | — | CN | disclosed |
| US-20240116917-A1 | ISO-CITRATE DEHYDROGENASE (IDH) INHIBITOR | ZHEJIANG METON PHARMACEUTICAL CO., LTD (CN) | 2024-04-11 | — | — | US | disclosed |
| US-20220274982-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-09-01 | — | — | US | disclosed |
| EP-4005638-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2022-06-01 | — | — | EP | disclosed |
| CN-114555597-A | Isocitrate Dehydrogenase (IDH) inhibitors | 浙江迈同生物医药有限公司 | 2022-05-27 | — | — | CN | disclosed |
| WO-2021068698-A1 | ISO-CITRATE DEHYDROGENASE (IDH) INHIBITOR | SHANGHAI METON PHARMACEUTICAL CO., LTD (CN) | 2021-04-15 | — | — | WO | disclosed |
| WO-2021068698-A1 | ISO-CITRATE DEHYDROGENASE (IDH) INHIBITOR | SHANGHAI METON PHARMACEUTICAL CO., LTD (CN) | 2021-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116917-A1 | ISO-CITRATE DEHYDROGENASE (IDH) INHIBITOR | IDH2, IDH3A, IDH1 | NPC1 1911/4885ALDH1A1 538/4885TP53 39/4885 |
| US-12528802-B2 | Heterocyclic compound | GBA2, GBA1, GALC | NPC1 81/4885ALDH1A1 2563/4885TP53 4852/4885 |
| US-20220274982-A1 | HETEROCYCLIC COMPOUND | GBA1, GBA2, GALC | NPC1 226/4885ALDH1A1 1563/4885TP53 4290/4885 |
| US-12441725-B2 | ISO-citrate dehydrogenase (IDH) inhibitor | IDH2, IDH3A, IDH1 | NPC1 1911/4885ALDH1A1 538/4885TP53 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.